InSilico Medicine Cayman TopCo (HKG:3696)

Market Cap	22.42B
Revenue (ttm)	1.06B +152.0%
Net Income	-2.33B
EPS	-7.14
Shares Out	575.84M
PE Ratio	n/a
Forward PE	35.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,335,490
Open	39.50
Previous Close	38.00
Day's Range	38.78 - 40.04
52-Week Range	29.98 - 80.90
Beta	n/a
Analysts	Strong Buy
Price Target	81.37 (+108.96%)
Earnings Date	Aug 26, 2026

About HKG:3696

InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, softwar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 333
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3696

Financial Performance

In 2025, HKG:3696's revenue was $56.24 million, a decrease of -34.48% compared to the previous year's $85.83 million. Losses were -$352.32 million, 1960.8% more than in 2024.

Financial numbers in USD

Analyst Summary

According to 10 analysts, the average rating for 3696 stock is "Strong Buy." The 12-month stock price target is $81.37, which is an increase of 108.96% from the latest price.

Price Target

$81.37

(108.96% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error